Treatment
Eltrombopag clinical trials
We’re tracking 14 recruiting studies that include Eltrombopag, each written for real people, not researchers, below.
Recruiting studies
- NCT04518475RecruitingPhase 4
Eltrombopag with rituximab versus eltrombopag alone for ITP
This trial compares two treatment approaches for adults with primary immune thrombocytopenia (ITP), a condition where platelet counts are too low. It looks at whether adding rituximab to eltrombopag helps control ITP better and more safely.
TianjinAges 18–60 - NCT04600960RecruitingPhase 2
Eltrombopag to raise low platelets after chemotherapy
This Phase 2 study tests eltrombopag to help people with low platelet counts caused by chemotherapy (which can increase bleeding risk). It looks at whether raising platelets can reduce bleeding problems and help you stay on track with care.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT04304820RecruitingPhase 2
Testing early oral cyclosporine and eltrombopag for severe anemia
This Phase 2 study tests whether starting two oral medicines early—cyclosporine and eltrombopag—can improve severe aplastic anemia in people who have not had prior treatment for it. It may help your blood counts recover without needing stronger or earlier treatments.
Bethesda, MarylandAges 3–99 - NCT05961410RecruitingPhase 2
Eltrombopag to help collect stem cells for lymphoma treatment
This Phase 2 study tests eltrombopag to improve collection of peripheral blood stem cells in adults with Hodgkin or non-Hodgkin lymphoma. If you’re getting a planned chemotherapy mobilization (like ESHAP, with or without an antibody), this trial may see whether eltrombopag can help your body collect the needed stem cells for transplant or further treatment.
TaipeiAges 18 years+ - NCT06531018RecruitingPhase 1/Phase 2
Eltrombopag for newly diagnosed ITP patients
This trial tests if eltrombopag, a medication that helps the body make more platelets, works as the first treatment for people newly diagnosed with immune thrombocytopenia (ITP, a condition where the immune system destroys platelets, causing bleeding problems). It may help raise your platelet count and reduce bleeding risk.
DhakaAges 18–70 - NCT07093606Recruiting
Eltrombopag and liver function in ITP patients
This study looks at how the drug eltrombopag affects the liver in people with primary ITP (immune thrombocytopenic purpura), a condition where the immune system destroys platelets. It aims to check if liver problems develop during treatment and who might be at higher risk.
SohagAges 18–75 - NCT07788456RecruitingPhase 4
Sequential combination therapy for newly diagnosed ITP in adults
This study tests a combination of multiple drugs given in sequence to adults with newly diagnosed immune thrombocytopenia (ITP), a condition of low platelets. The goal is to see if this approach improves platelet counts and is safe.
TianjinAges 18–75 - NCT07113743Enrolling by invitationPhase 1/Phase 2
Gene therapy for x-linked chronic granulomatous disease
This trial tests a new gene therapy for X-linked chronic granulomatous disease (CGD), a condition where the immune system cannot fight certain infections. The treatment uses your own blood stem cells, which are modified in the lab to help your body produce working immune cells.
Bethesda, MarylandAges 3–60 - NCT06479291Recruiting
HCQ plus TPO-RA for ANA positive ITP
This trial tests if combining two medicines (HCQ and a TPO-RA) can help people with a type of low platelet count called ITP who also have a positive ANA blood test. The goal is to see if this combination works better than standard treatments.
Shanghai, Shanghai MunicipalityAges 15–99 - NCT07587723Recruiting
Real-world study of eltrombopag treatment in immune thrombocytopenia
This study looks at how doctors treat immune thrombocytopenia (ITP)—a blood condition where your body attacks its own platelets—using a drug called eltrombopag. Researchers want to understand treatment patterns and outcomes in real-world practice to improve care.
BaselAges 18–100 - NCT03844360RecruitingPhase 4
Personalized dosing of cancer or infection medicines in children
This trial looks at how to adjust the dose of cancer medicines and/or anti-infection medicines in children who have blood-related cancers. The goal is to make dosing fit each child’s needs while they receive standard treatment.
Xuzhou, JiangsuAges 1 day–18 years - NCT06287268Recruiting
Revolade (eltrombopag) study for children with aplastic anemia
This trial is for children and teenagers (ages 6 to 17) with aplastic anemia who are starting eltrombopag (Revolade) for the first time, taken together with ATG (a medicine that helps the immune system). The study will monitor how well the treatment works and how safe it is.
Nagoya, Aichi-kenAges 6–17 - NCT06345495RecruitingPhase 2
High-dose ruxolitinib and stem cell transplant for enlarged spleen in myelofibrosis
This trial tests a higher dose of ruxolitinib before a stem cell transplant for people with myelofibrosis who have an enlarged spleen. It aims to see if this approach helps the transplant work better.
Houston, TexasAges 18–75 - NCT05049668Enrolling by invitation
Long-term follow-up for people from the RACE study
This study checks on people who took part in the earlier RACE trial and collected long-term health information. It helps researchers understand how the treatments given in that trial affect patients over time.
ParisAges Any age
What Eltrombopag is being studied for
Conditions with recruiting Eltrombopag studies.
Common questions
- Are there clinical trials studying Eltrombopag?
- Yes. Clin2 currently lists 14 recruiting studies that include Eltrombopag, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a Eltrombopag trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is Eltrombopag an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether Eltrombopag or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.